Question:
A 65-year-old man with chronic systolic heart failure (HFrEF) is started on medical therapy. Which of the following drugs has been shown to reduce mortality in HFrEF?
Options:
A. Furosemide
B. Digoxin
C. ACE inhibitors (e.g., Enalapril)
D. Nitrates alone
✅ Answer: C. ACE inhibitors (e.g., Enalapril)
Explanation:
HFrEF (EF <40%) management includes drugs that improve survival, reduce hospitalization, and relieve symptoms.
ACE inhibitors / ARBs:
Reduce mortality and morbidity.
Decrease afterload, inhibit maladaptive RAAS activation, reduce LV remodeling.
Beta-blockers (e.g., Carvedilol, Metoprolol succinate):
Also improve survival in chronic HFrEF.
Reduce sympathetic overdrive, prevent arrhythmias, improve EF over time.
Mineralocorticoid receptor antagonists (e.g., Spironolactone):
Reduce mortality in selected patients with HFrEF (EF ≤35%).
Furosemide (loop diuretic):
Symptomatic relief (reduces congestion) but does not improve survival.
Digoxin:
Improves symptoms and reduces hospitalization, no proven mortality benefit.
Nitrates alone:
May reduce preload but do not reduce mortality unless combined with hydralazine (especially in African-American patients).
References:
Harrison’s Principles of Internal Medicine, 21st Edition, Ch. 220;
Braunwald’s Heart Disease, 12th Edition, Ch. 43;
UpToDate: Chronic HFrEF management.
Comments
Post a Comment